Drug Trial Radar · NCT06544330
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
Apr 2028
Study completion Apr 2041
Sponsor
- Lead sponsor
- SynthekineIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
Conditions
- Systemic Lupus Erythematosus
- Lupus Nephritis
- Systemic Sclerosis
Interventions
SYNCAR-001Drug
SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb
STK-009Drug
STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicities (DLTs)Time frame: Up to 28 days after SYNCAR-001 infusion
- Adverse EventsTime frame: Up to 96 weeks after SYNCAR-001 infusion
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
Hackensack University Medical Center
Hackensack, New Jersey
Feinstein Institutes for Medical Research
Manhasset, New York
Columbia University Irving Medical Center
New York, New York
The Cleveland Clinic Foundation
Cleveland, Ohio
Ohio State University Wexner Medical Center
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.